This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OSI Shares Soar After Astellas Hostile Bid

MELVILLE. N.Y. ( TheStreet) -- OSI Pharmaceuticals (OSIP) shares soared almost 52% Monday after it said it would review an unsolicited takeover proposal from Japanese drugmaker Astellas Pharma with its advisers.

But the chances of OSI accepting the bid are low as it rejected a similar oral proposal from Astellas in February.

Astellas on Monday launched a hostile tender offer of $3.5 billion for OSI, the maker of the lung cancer drug Tarceva. Astellas' offer of $52 a share was a 40% premium over OSI's closing price Friday of $37.02.

The tender offer is expected to begin Tuesday.

OSI shares gained $19.23 on Monday to close at $56.25, in anticipation that OSI could receive a higher bid.

Astellas said its hostile tender offer for OSI comes after numerous previous attempts to buy the U.S. drug company were turned away.

In a press release Monday, following news of the Astellas bid, OSI released a copy of a letter dated Feb. 22 in which it rejected an oral proposal of $52 a share from Astellas, saying it wasn't "interested in undertaking a sale of OSI at that price, since it believes Astellas' proposal very significantly undervalues the company."

In responding to the February proposal, OSI said it offered to provide Astellas with non-public information which it said was fundamental to its valuation of OSI. The response to that letter was Astellas' unsolicited proposal, OSI said.

-- Reported by Joseph Woelfel in New York.

Follow on Twitter and become a fan on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs